Table I.
Characteristics of patients treated with cabazitaxel.
| Characteristic | Value (N=45) |
|---|---|
| Age, years, median (range) | 71 (46–85) |
| Age group, n (%) | |
| <75 years | 37 (85.4) |
| 75-years | 8 (14.6) |
| ECOG PS, n (%) | |
| 0 | 38 (87.8) |
| 1, 2 | 7 (12.2) |
| PSA at baseline, ng/ml, median (range) | 124.3 (0.17–11,660) |
| Sites involved, n (%) | |
| Bone | 44 (97.8) |
| Lymph nodes | 17 (38.6) |
| Visceral metastasis | 13 (9.1) |
| Prior surgery, n (%) | 10 (22.7) |
| Prior radiotherapy, n (%) | 20 (43.2) |
| Prior 2nd AR targeting lines, n (%) | |
| ENZA/ABI | 29 (60.9)/22 (48.9) |
| Prior docetaxel-containing regimens, n (%) | |
| 1, 2 | 11 (7.3) |
| 3 | 17 (37.8) |
| 4 or more | 17 (37.8) |
| Total prior docetaxel cycle, median (range) | 8 (3–43) |
| PSA at baseline, ng/ml, median (range) | 124.3 (0.17–11,660) |
| Hb at baseline, g/dl, median (range) | 11.5 (9.2–14.8) |
| AMC at baseline, /µl, median (range) | 398 (114–941) |
| NLR at baseline, median (range) | 4.3 (1.2–16.0) |
| ALP at baseline, IU/l, median (range) | 293 (313–3,146) |
ECOG PS, Eastern Cooperative Oncology Group performance status; PSA, prostate-specific antigen; ENZA, Enzalutamide; ABI, abiraterone; Hb, hemoglobin; ALP, al; AMC, absolute monocyte count; NLR, Neutrophil to Lynphocyte ratio.